BCL2 and diabetic cardiomyopathy: Mechanically, CSF administration reduced autophagosomes, lowered the ratio of LC3II/LC3I, increased Bcl-2 and p-AKT expression, decreased miR-34a expression in HG-induced H9C2 cells [36], which suggested that targeting AKT/Bcl2/(LC3II/LC3I) axis might be a possible way of CSF in diabetic cardiomyopathy therapy.